All In MedTech

FDA Clearance Tracker · P970042-S001

MEDSTONE STS LITHOTRIPTER

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 5, 2001 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P970042-S001
Device name
MEDSTONE STS LITHOTRIPTER
Applicant location
Aliso Viejo, CA
Received
Dec 18, 2000
Decided
Feb 5, 2001
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Postapproval Study Protocol
Original approval
P970042

Device type

Device class
Class III

Every decision under product code NCV

FDA's approval statement

As written in FDA's record.

APPROVAL FOR SEVERAL CHANGES TO THE POST-APPROVAL STUDY PROTOCOL. SPECIFICALLY, THESE CHANGES ARE 1) CHANGES TO INCLUSION CRITERIA 3 AND 5 2) CHANGES TO EXCLUSION CRITERIA 7, 8, 9, 10, 11, 13, 15, AND 16 3) ELIMINATION OF THE ULTRASOUND EVALUATION IMMEDIATELY POST-LITHOTRIPSY, 4) ELIMINATION OF THE ORAL CHOLECYSTOGRAM AT THE SIX-MONTH VISIT, AND 5) ADDITION OF STATEMENTS TO CLARIFY GUIDELINES FOR SCHEDULING FOLLOW-UP VISITS AND TO LIST PROTOCOL REQUIREMENTS BY STUDY VISIT.

Source documents

Other decisions for Medstone Intl., Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.